Literature DB >> 10875289

Prevalence of hepatitis C virus seropositivity among hospitalized US veterans.

G E Austin1, B Jensen, J Leete, W De L'Aune, J Bhatnagar, M Racine, J E Braun.   

Abstract

BACKGROUND: Hepatitis C virus (HCV) is a major cause of acute and chronic hepatitis in the United States and abroad. HCV antibody prevalences ranging from 10 to 90% have been reported in intravenous drug abusers, hemodialysis patients, and persons suffering from other liver diseases, whereas HCV seropositivity rates for volunteer-blood donor populations are generally under 1%. However no information has been available concerning the prevalence of HCV in general hospital populations in the United States.
METHODS: We examined the rate of HCV seropositivity in 530 patients admitted to the Atlanta VA Medical Center between November 1993 and November 1994. The test population consisted of 400 random hospital admissions, 100 successive admissions to the surgical service, and 30 random admissions to the gastrointestinal service. Serum samples were assayed for HCV antibodies by a second generation EIA, and all repeat reactives were re-examined using a supplemental research assay to confirm the presence of HCV antibodies. Complete chart reviews were carried out on all HCV seropositive patients and on 100 HCV seronegative patients.
RESULTS: Sixty-two of the 530 patients tested (11.7%) were repeatedly positive for HCV antibodies. Of these 62 repeat reactives, 56 (90.3%) were positive and 3 others (4.8%) indeterminate by the supplemental assay. The HCV seropositivity rate after supplemental testing was 11.8% for random admissions, 5.0% for surgical admissions, and 13.3% for patients admitted to the gastroenterology service. HCV-associated risk factors in HCV seropositive patients included a history of intravenous drug abuse, current or previous alcohol abuse, previous or concurrent liver disease, previous blood transfusions, hemodialysis, and multiple sex partners or unsafe sex.
CONCLUSIONS: HCV infection may be more prevalent among hospitalized VA patients (and among other US hospital populations) than previously expected.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10875289     DOI: 10.1097/00000441-200006000-00002

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  7 in total

1.  Toward a more accurate estimate of the prevalence of hepatitis C in the United States.

Authors:  Brian R Edlin; Benjamin J Eckhardt; Marla A Shu; Scott D Holmberg; Tracy Swan
Journal:  Hepatology       Date:  2015-08-25       Impact factor: 17.425

Review 2.  Estimating the true prevalence of hepatitis C in rhode island.

Authors:  Elizabeth N Kinnard; Lynn E Taylor; Omar Galárraga; Brandon D L Marshall
Journal:  R I Med J (2013)       Date:  2014-07-01

3.  Racial differences in the evaluation and treatment of hepatitis C among veterans: a retrospective cohort study.

Authors:  Christine M Rousseau; George N Ioannou; Jeffrey A Todd-Stenberg; Kevin L Sloan; Meaghan F Larson; Christopher W Forsberg; Jason A Dominitz
Journal:  Am J Public Health       Date:  2008-04-01       Impact factor: 9.308

4.  Risk of hepatitis C virus transmission from patients to surgeons: model based on an unlinked anonymous study of hepatitis C virus prevalence in hospital patients in Glasgow.

Authors:  D Thorburn; K Roy; S O Cameron; J Johnston; S Hutchinson; E A B McCruden; P R Mills; D J Goldberg
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

5.  Risk profile of hepatocellular carcinoma reveals dichotomy among US veterans.

Authors:  Raffi Karagozian; Errol Baker; Antoun Houranieh; Daniel Leavitt; György Baffy
Journal:  J Gastrointest Cancer       Date:  2013-09

6.  Risk factors for hepatitis C virus infection among patients receiving health care in a Department of Veterans Affairs hospital.

Authors:  Girish Mishra; C Sninsky; Robert Roswell; S Fitzwilliam; Kenneth C Hyams
Journal:  Dig Dis Sci       Date:  2003-04       Impact factor: 3.199

7.  Impact and costs of a hepatitis C virus screening programme for adults hospitalised at an academic medical centre.

Authors:  Timothy J Whitman; Cindy D Noyes; Andrew J Hale; Devika Singh; Stephen G DeVoe; Allen B Repp; Kristen K Pierce; Louis B Polish; Beth D Kirkpatrick; Jean Dejace; Lindsay M Smith; Tim Lahey; Christopher D Huston; Laura J Catoe; Prateek Ghatage; Sean Bullis; W Kemper Alston
Journal:  BMJ Open Qual       Date:  2021-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.